3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
7
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
1112
Recurrence
195
Neoplasms
89
Lymphoma
89
Neoplasms, Plasma Cell
88
Lymphoma, Non-Hodgkin
86
Leukemia, Myeloid, Acute
53
Hematologic Neoplasms
51
Leukemia, Lymphocytic, Chronic, B-Cell
44
Leukemia
37
Myelodysplastic Syndromes
33
Lymphoma, Large B-Cell, Diffuse
31
Hodgkin Disease
31
Immunoglobulin Light-chain Amyloidosis
30
Breast Neoplasms
30
Precursor Cell Lymphoblastic Leukemia-Lymphoma
26
Hematologic Diseases
25
Prostatic Neoplasms
19
Paraproteinemias
19
Lymphoma, B-Cell
19
Amyloidosis
19
Lymphoma, Mantle-Cell
18
Ovarian Neoplasms
17
Carcinoma, Non-Small-Cell Lung
17
Waldenstrom Macroglobulinemia
16
Lung Neoplasms
16
Lymphoma, Follicular
15
Lymphoproliferative Disorders
14
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
14
Blood Protein Disorders
14
Interventions
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Amyloid Neuropathies, Familial
×
Plasma cell
×
Clear all
NCT05184088
2026-06-02
CArdiag
Lantheus Biosciences Ltd.
Phase 3
Completed
244 enrolled